Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Thoracic 4Gastrointestinal 4Tumor-Agnostic 3Plasma cell 2Sarcoma 1Head & Neck 1CNS 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × dostarlimab × Plasma cell × Clear all
NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Terminated
4 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡